ANTABIO has developed a portfolio of first-in-class programs targeting high unmet needs in the antibacterial space. In 2013 ANTABIO received a €4.7 Million Wellcome Trust Seeding Drug Discovery Award to fund the development of a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases up to preclinical candidate nomination. In 2015 ANTABIO received a second Wellcome Trust Seeding Drug Discovery Award (€4.0 Million) to support the development of novel small molecule drugs for the treatment of chronic Pseudomonas infections in Cystic Fibrosis (CF) patients, and this lead subsequently in 2017 to a CARB-X award (potentially up to $8.9 Million) to continue development up to clinical trials.
Fighting Hospital Infections. Antibiotic resistance is a growing global health problem recognized as n°1 priority by the WHO. 5-10% of hospital patients in US and Europe develop a hospital-acquired (nosocomial) infection with annual > €30 billion additional costs to public health and > 100,000 deaths due to drug-resistant bacterial infections. In the horizon 2050, alarming reports claim that antimicrobial resistance will kill more than 10 million people each year. Current antibacterial chemotherapy is becoming increasingly inadequate due to the rise of resistance, mainly related to the spread of genes encoding various carbapenemases, including: a) metallo beta-lactamase (MBL) enzymes, such as NDM, which are highly prevalent throughout the Asia Pacific region and for which no inhibitors are currently available, and b) serine beta-lactamase (SBL) enzymes, such as OXA and KPC, which are widespread in North America and Europe and for which better broad-spectrum inhibitors are required.